Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors

被引：0

作者：

Diab, Adi ^{[1
]}

Tannir, Nizar ^{[1
]}

Cho, Daniel ^{[2
]}

Papadimitrakopoulou, Vali ^{[1
]}

Bernatchez, Chantale ^{[1
]}

Haymaker, Cara ^{[1
]}

Bentebibel, Salah Eddine ^{[1
]}

Curti, Brendan ^{[3
,4
]}

Wong, Michael ^{[1
]}

Tykodi, Scott ^{[5
,6
]}

Puzanoff, Igor ^{[7
]}

Smalberg, Ira ^{[7
]}

Gergel, Ivan ^{[8
]}

Tagliaferri, Mary ^{[8
]}

Zalevsky, Jonathan ^{[8
]}

Hoch, Ute ^{[8
]}

Aung, Sandra ^{[8
]}

Imperiale, Michael ^{[8
]}

Clemens, Wendy ^{[9
]}

Kluger, Harriet ^{[10
]}

Hurwitz, Michael ^{[10
]}

Hwu, Patrick ^{[1
]}

Sznol, Mario ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] NYU Med Oncol Associates, New York, NY USA

[3] Providence Canc Ctr, Portland, OR USA

[4] Earle A Chiles Res Inst, Portland, OR USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Nektar Therapeut, San Francisco, CA USA

[9] Bristol Myers Squibb, Lawrence Township, NJ USA

[10] Yale Sch Med, New Haven, CT USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O20

引用

页数：1

共 50 条

[21] NKTR-255+CETUXIMAB IN PATIENTS WITH SOLID TUMORS: INTERIM SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B DOSE-ESCALATION STUDY
Altan, Mehmet
Patnaik, Amita
Barve, Minal
Dunn, Lara
Cobb, Patrick
Rosenberg, Ari
Sharma, Sunil
Sukari, Ammar
Patel, Manish
Wang, Xiaoli
Ma, Haijun
Dixit, Neha
Nieves, Wildaliz
Fanton, Christie
Currie, Sue
Lee, Zachary
Marcondes, Mario
Zalevsky, Johnathan
Tagliaferri, Mary
Sacco, Assuntina
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1007 - A1007
[22] An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results
Harrington, K. J.
Sacco, J. J.
Olsson-Brown, A.
Chan, T.
Nenclares, P.
Leslie, I.
Bommareddy, P.
Ahlers, C.
Wolff, J.
Middleton, M. R.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S926 - S927
[23] Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
Koshkin, Vadim S.
Sonpavde, Guru P.
Hwang, Clara
Mellado, Begona
Tomlinson, Gareth
Shimura, Masashi
Chisamore, Michael Jon
Gil, Maciej
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[24] A phase 1 multiple ascending dose study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors.
Luke, Jason J.
Olszanski, Anthony J.
Puzanov, Igor
Lu, Dan
Hackett, Adrian
Martomo, Stella
Patel, Jeegar
Schueller, Olivier
Mora, Alessandro
Schlitt, Miranda L.
Li, Linghui
CANCER RESEARCH, 2021, 81 (13)
[25] Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxoliplatin in patients with advanced or metastatic solid tumours:: Results from a phase I study.
Evans, J
Tabernero, J
Cassidy, J
Sastre, J
Eatock, M
Baselga, J
Bissett, D
Regueiro, P
Rubio, ED
ANNALS OF ONCOLOGY, 2000, 11 : 51 - 51
[26] Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
Hu, Xichun
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Wu, Junyan
Wang, Ying
Hao, Yanrong
Ge, Junyou
Qing, Yan
Yi, Shuli
Yang, Qixian
Rao, Huajing
Yuan, Juanjuan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
Janku, Filip
Birrer, Michael
Richardson, Debra
Chu, Christina
Goel, Sanjay
Su, Ying
Matin, Bahar
Kuida, Keisuke
Ruiz-Soto, Rodrigo
Hamilton, Erika Paige
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[28] The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-in-human phase 1/2 study
Liu, S.
Zhang, J.
Chen, Z.
Zhang, Y.
Wang, J.
Chen, Y.
Chen, J.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S32 - S32
[29] Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II.
Lopez Martin, Ana
Bellmunt, Joaquim
Pablo Maroto, Jose
Gallardo, Enrique
Lopez Brea, Marta
Luis Perez-Gracia, Jose
Castellano, Daniel E.
Maria Valverde, Claudia
Bezares, Susana
Calvo, Emiliano
Paz-Ares, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[30] Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Powles, Thomas
O'Donnell, Peter H.
Massard, Christophe
Arkenau, Hendrik-Tobias
Friedlander, TerenceW.
Hoimes, Christopher J.
Lee, Jae Lyun
Ong, Michael
Sridhar, Srikala S.
Vogelzang, Nicholas J.
Fishman, Mayer N.
Zhang, Jingsong
Srinivas, Sandy
Parikh, Jigar
Antal, Joyce
Jin, Xiaoping
Gupta, Ashok K.
Ben, Yong
Hahn, Noah M.
JAMA ONCOLOGY, 2017, 3 (09)

← 1 2 3 4 5 →